Advertisement

Clinical and Translational Oncology

, Volume 17, Issue 4, pp 264–273 | Cite as

Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

  • P. García-AlfonsoEmail author
  • J. García-Foncillas
  • R. Salazar
  • P. Pérez-Segura
  • R. García-Carbonero
  • E. Musulén-Palet
  • M. Cuatrecasas
  • S. Landolfi
  • S. Ramón y Cajal
  • S. Navarro
Clinical Guides in Oncology

Abstract

Publication of this consensus statement is a joint initiative of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM), intended to revise and update the diagnostic and treatment recommendations published 2 years ago on biomarker use and the management of patients with colorectal carcinoma (CRC), thereby providing an opportunity to improve healthcare efficiency and resource use in these patients. This expert group recommends testing for KRAS and NRAS status in all patients with metastatic CRC being considered for anti-epidermal growth factor receptor (anti-EGFR) therapy, as this type of treatment should only be used in patients not harbouring mutations in these genes. In contrast, testing for BRAF, EGFR, PI3K and PTEN mutation status is not necessary for therapeutic decision making, so does not need to be done routinely.

Keywords

Biomarkers CRC EGFR KRAS NRAS 

Notes

Acknowledgments

The authors are grateful for the editorial assistance of Ana Martín of HealthCo (Madrid, Spain) in the production of this manuscript. SEOM and SEAP are grateful for financial support for this project in the form of unrestricted grants from Merck, Sanofi and Roche.

Conflict of interest

The authors declare that, when writing and revising the text, they did not know the names of the pharmaceutical companies that provided financial support for this project, so this support has not influenced the content of this article.

References

  1. 1.
    Garcia-Alfonso P, Salazar R, Garcia-Foncillas J, Musulen E, Garcia-Carbonero R, Paya A, et al. Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol. 2012;14:726–39.CrossRefPubMedGoogle Scholar
  2. 2.
    Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1986;89:2S–3S.CrossRefPubMedGoogle Scholar
  4. 4.
    Gray RG, Barnwell J, Hills R, McConkey C, Williams N, Kerr D. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. ASCO Meeting Abstracts. 2004;22:3501.Google Scholar
  5. 5.
    Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, et al. Validation study of a quantitative multigene reverse transcriptase polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29:4611–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31:1775–81.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Yothers G, O’Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol. 2013;31:4512–9.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Tabernero J, Moreno V, Rosenberg R, Nitsche U, Bachleitner-Hofmann T, Lanza G, et al. Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of patients with stage II colon cancer. ASCO Meeting Abstracts. 2012;30:384.Google Scholar
  9. 9.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  10. 10.
    Washington MK, Berlin J, Branton P, Burgart LJ, Carter DK, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Based on AJCC/UICC TNM. 7th edn; 2013.Google Scholar
  11. 11.
    Lo DS, Pollett A, Siu LL, Gallinger S, Burkes RL. Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer. Cancer. 2008;112:50–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Capelli P, Chilosi M, et al. Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging. Mod Pathol. 2007;20:843–55.CrossRefPubMedGoogle Scholar
  13. 13.
    Fitzgibbons PL, Bradley LA, Fatheree LA, Alsabeh R, Fulton RS, Goldsmith JD, et al. Principles of analytic validation of immunohistochemical assays: guideline from the college of american pathologists pathology and laboratory quality center. Arch Pathol Lab Med. 2014;138:1432–43.Google Scholar
  14. 14.
    Schrijver I, Aziz N, Jennings LJ, Richards CS, Voelkerding KV, Weck KE. Methods-based proficiency testing in molecular genetic pathology. J Mol Diagn. 2014;16:283–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Bartley AN, Hamilton SR, Alsabeh R, Ambinder EP, Berman M, Collins E, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. Arch Pathol Lab Med. 2014;138:166–70.CrossRefPubMedGoogle Scholar
  16. 16.
    Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Greenson JK, Bonner JD, Ben-Yzhak O, Cohen HI, Miselevich I, Resnick MB, et al. Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol. 2003;27:563–70.CrossRefPubMedGoogle Scholar
  18. 18.
    Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32:2240–7.Google Scholar
  19. 19.
    Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.CrossRefPubMedGoogle Scholar
  20. 20.
    Tejpar S, Lenz H-J, Kohne C-H, Heinemann V, Ciardiello F, Esser R, et al. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. ASCO Meeting Abstracts. 2014;32:LBA444.Google Scholar
  21. 21.
    Ciardiello F, Lenz H-J, Kohne C-H, Heinemann V, Tejpar S, Melezinek I, et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. ASCO Meeting Abstracts. 2014;32:3506.Google Scholar
  22. 22.
    Hernández-Losa J, Sanz J, Landolfi S, López-Ríos F, Palacios J, Bautista MD, et al. Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon. Rev Esp Patol. 2012;45:76–85.Google Scholar
  23. 23.
    Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72:4875–82.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501:328–37.CrossRefPubMedGoogle Scholar
  25. 25.
    Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.CrossRefPubMedGoogle Scholar
  26. 26.
    Kosmidou V, Oikonomou E, Vlassi M, Avlonitis S, Katseli A, Tsipras I, et al. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. Hum Mutat. 2014;35:329–40.CrossRefPubMedGoogle Scholar
  27. 27.
    Bossard C, Kury S, Jamet P, Senellart H, Airaud F, Ramee JF, et al. Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas. J Clin Pathol. 2012;65:466–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Perez K, Walsh R, Brilliant K, Noble L, Yakirevich E, Breese V, et al. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. Exp Mol Pathol. 2013;95:74–82.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Baas JM, Krens LL, Guchelaar HJ, Morreau H, Gelderblom H. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist. 2011;16:1239–49.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Lamy A, Blanchard F, Le Pessot F, Sesboue R, Di Fiore F, Bossut J, et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol. 2011;24:1090–100.CrossRefPubMedGoogle Scholar
  31. 31.
    Improta G, Zupa A, Possidente L, Tartarone A, Pedicini P, Nappi A, et al. Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity. Oncol Lett. 2013;5:1741–3.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Engel KB, Moore HM. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2011;135:537–43.PubMedGoogle Scholar
  33. 33.
    Wester K, Wahlund E, Sundstrom C, Ranefall P, Bengtsson E, Russell PJ, et al. Paraffin section storage and immunohistochemistry. Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigen. Appl Immunohistochem Mol Morphol. 2000;8:61–70.PubMedGoogle Scholar
  34. 34.
    Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3:658–73.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537–40.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012;18:221–3.CrossRefPubMedGoogle Scholar
  38. 38.
    Vilar E, Tabernero J. Cancer: pinprick diagnostics. Nature. 2012;486:482–3.CrossRefPubMedGoogle Scholar
  39. 39.
    Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23:2313–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra224.Google Scholar
  41. 41.
    Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20:430–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2:227–35.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100–3.CrossRefPubMedGoogle Scholar
  44. 44.
    Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012;72:3228–37.CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753–62.CrossRefPubMedGoogle Scholar
  46. 46.
    Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261–70.CrossRefPubMedGoogle Scholar
  47. 47.
    Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466–74.CrossRefPubMedGoogle Scholar
  48. 48.
    Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22:1535–46.CrossRefPubMedGoogle Scholar
  49. 49.
    Knijn N, Mekenkamp LJ, Klomp M, Vink-Borger ME, Tol J, Teerenstra S, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011;104:1020–6.CrossRefPubMedCentralPubMedGoogle Scholar
  50. 50.
    Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27:5931–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563–72.CrossRefPubMedGoogle Scholar
  53. 53.
    Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res. 2013;19:1902–12.CrossRefPubMedGoogle Scholar
  54. 54.
    Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Spindler KL, Andersen RF, Jensen LH, Ploen J, Jakobsen A. EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. Ann Oncol. 2010;21:535–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279–86.CrossRefPubMedGoogle Scholar
  57. 57.
    Rodriguez J, Zarate R, Bandres E, Boni V, Hernandez A, Sola JJ, et al. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur J Cancer. 2012;48:1774–80.CrossRefPubMedGoogle Scholar
  58. 58.
    Stintzing S, Jung A, Rossius L, Modest DP, Fischer von Weikersthal L, Decker T, et al. Mutations within the EGFR signaling pathway: influence on efficacy in FIRE-3—a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. J Clin Oncol. 2014;32:abstract 445.Google Scholar
  59. 59.
    Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27:5924–30.CrossRefPubMedGoogle Scholar
  60. 60.
    Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bonasoni MP, Camisa R, et al. PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer. 2010;102:162–4.CrossRefPubMedCentralPubMedGoogle Scholar
  61. 61.
    Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. 2006;3:551–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA. 1999;96:9236–9241.Google Scholar
  63. 63.
    Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 2008;14:579–84.CrossRefPubMedGoogle Scholar
  64. 64.
    Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347–51.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2014

Authors and Affiliations

  • P. García-Alfonso
    • 1
    Email author
  • J. García-Foncillas
    • 2
  • R. Salazar
    • 3
  • P. Pérez-Segura
    • 4
  • R. García-Carbonero
    • 5
  • E. Musulén-Palet
    • 6
  • M. Cuatrecasas
    • 7
  • S. Landolfi
    • 8
  • S. Ramón y Cajal
    • 8
  • S. Navarro
    • 9
  1. 1.Department of Medical Oncology, Servicio de Oncología MédicaHospital General Universitario Gregorio MarañónMadridSpain
  2. 2.Department of Medical OncologyFundación Jiménez DíazMadridSpain
  3. 3.Department of Medical OncologyICO Hospital Duran i Reynals, Hospitalet de LlobregatBarcelonaSpain
  4. 4.Department of Medical OncologyHospital Clínico Universitario San CarlosMadridSpain
  5. 5.Department of Medical OncologyHospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (HUVR, CSIC, University of Seville)SevilleSpain
  6. 6.Department of PathologyHospital Universitari Germans Trias i PujolBadalonaSpain
  7. 7.Department of PathologyHospital ClinicBarcelonaSpain
  8. 8.Department of PathologyHospital Universitario Vall d’HebronBarcelonaSpain
  9. 9.Department of PathologyHospital Clínico Universitario de ValenciaValenciaSpain

Personalised recommendations